Huntington disease
Information
- Disease name
- Huntington disease
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04556656 | Active, not recruiting | Phase 3 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | October 16, 2020 | March 14, 2024 |
| NCT02728115 | Active, not recruiting | Phase 1 | Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease | October 16, 2017 | December 31, 2023 |
| NCT04270604 | Active, not recruiting | Biological Sample Collection for Research and Biobanking | February 6, 2012 | January 2030 | |
| NCT00051324 | Active, not recruiting | Neurobiological Predictors of Huntington's Disease (PREDICT-HD) | August 2002 | June 30, 2024 | |
| NCT04219241 | Active, not recruiting | Phase 2/Phase 3 | Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. | February 10, 2020 | December 2022 |
| NCT05769972 | Active, not recruiting | N/A | Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders | October 13, 2021 | December 1, 2023 |
| NCT06391619 | Active, not recruiting | Huntington's Disease Young Adult Study 2.0 | April 6, 2022 | December 1, 2025 | |
| NCT04406636 | Active, not recruiting | Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD | May 19, 2020 | April 2023 | |
| NCT06209515 | Active, not recruiting | Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study | January 1, 2022 | December 31, 2027 | |
| NCT05541627 | Active, not recruiting | Phase 1/Phase 2 | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease | October 12, 2022 | December 31, 2029 |
| NCT00592995 | Completed | Phase 2 | Creatine Safety and Tolerability in Premanifest HD: PRECREST | December 2007 | September 2012 |
| NCT00632645 | Completed | Phase 3 | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride | April 2009 | April 28, 2017 |
| NCT00654563 | Completed | Memory Disorders Registry | August 2007 | March 2012 | |
| NCT00724048 | Completed | Phase 2 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease | October 24, 2008 | July 26, 2010 |
| NCT00788047 | Completed | Phase 1 | A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan | November 2008 | January 2009 |
| NCT00831506 | Completed | Phase 1 | Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects | February 2009 | May 2009 |
| NCT00870974 | Completed | Phase 1 | A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions | March 2009 | November 2016 |
| NCT00920946 | Completed | Phase 3 | A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease | July 2009 | |
| NCT00970229 | Completed | Phase 1 | Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. | July 2009 | May 2015 |
| NCT00980694 | Completed | Phase 1 | Bioavailability of Ubiquinol in Huntington Disease | September 2009 | July 2012 |
| NCT00988624 | Completed | Phase 1 | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | October 2009 | December 2009 |
| NCT01306929 | Completed | Phase 2 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | March 24, 2011 | January 5, 2018 |
| NCT01339130 | Completed | N/A | Assessment of Social-emotional Functioning in Neurological Diseases | June 2009 | June 2013 |
| NCT01357681 | Completed | Phase 2 | Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) | September 2011 | May 2015 |
| NCT01359774 | Completed | N/A | 31P-MRS and Huntington Disease | April 2011 | April 2012 |
| NCT05748288 | Completed | Development of the Virtual Unified Huntington's Disease Rating Scale | September 22, 2022 | May 2, 2023 | |
| NCT01458470 | Completed | Phase 2 | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease | September 2011 | November 2012 |
| NCT01485952 | Completed | Phase 1 | An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 | March 2011 | November 2011 |
| NCT01573819 | Completed | Phase 1 | A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | November 24, 2011 | April 2, 2012 |
| NCT01590589 | Completed | REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) | June 2004 | June 30, 2017 | |
| NCT01590888 | Completed | Phase 2 | Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease | April 2012 | February 2014 |
| NCT01602900 | Completed | Phase 1 | Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease | November 22, 2011 | April 12, 2012 |
| NCT01696708 | Completed | N/A | Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease | December 6, 2012 | November 2015 |
| NCT01834911 | Completed | Phase 4 | Effect of Tetrabenazine on Stroop Interference in HD | March 2013 | January 1, 2018 |
| NCT01842919 | Completed | N/A | Dance and Huntington Disease | April 2013 | July 8, 2016 |
| NCT01882062 | Completed | Phase 2 | Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease | May 2013 | July 2013 |
| NCT01884181 | Completed | Accelerated Diffusion MRI for Diagnosis of Hungtington Disease | January 2014 | December 2017 | |
| NCT01919034 | Completed | Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients | April 2012 | December 2012 | |
| NCT01937923 | Completed | A Pre-Cellular Therapy Observational Study in Early Huntington's Disease | August 2013 | July 2016 | |
| NCT05358821 | Completed | Phase 2 | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | June 22, 2022 | April 10, 2024 |
| NCT02268617 | Completed | N/A | Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease | February 2013 | September 2016 |
| NCT02336633 | Completed | N/A | Resveratrol and Huntington Disease | July 2015 | January 2020 |
| NCT02453061 | Completed | Phase 2 | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | June 29, 2015 | December 3, 2019 |
| NCT02464293 | Completed | N/A | A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease | June 2015 | January 31, 2018 |
| NCT02535884 | Completed | N/A | Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) | July 2014 | December 31, 2021 |
| NCT05268029 | Completed | Making HD Voices Heard | March 23, 2022 | October 11, 2023 | |
| NCT02727270 | Completed | Measuring Cortisol Levels in Persons With Parkinson's (PD) | June 2016 | November 16, 2023 | |
| NCT02814201 | Completed | Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm | July 2011 | November 2016 | |
| NCT02819700 | Completed | Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI) | January 29, 2013 | January 28, 2018 | |
| NCT05250323 | Completed | Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM) | May 14, 2021 | June 23, 2021 | |
| NCT05238701 | Completed | Phase 1 | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects | February 25, 2022 | November 4, 2023 |
| NCT05224115 | Completed | Dosimetry of [11C]CHDI-180R and [11C]CHDI-626. | July 17, 2020 | October 13, 2020 | |
| NCT05157074 | Completed | N/A | Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease | January 9, 2019 | June 10, 2019 |
| NCT05126862 | Completed | N/A | Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) | December 10, 2021 | July 9, 2023 |
| NCT04925622 | Completed | Complex Eye Movements in Parkinson's Disease and Related Movement Disorders | January 4, 2021 | April 15, 2022 | |
| NCT03193099 | Completed | N/A | Decoding Presymptomatic White Matter Changes in Huntington Disease | July 11, 2017 | December 30, 2019 |
| NCT04917133 | Completed | N/A | Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay | June 7, 2021 | December 7, 2021 |
| NCT03252535 | Completed | Phase 2 | Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease | January 15, 2018 | April 30, 2021 |
| NCT04701580 | Completed | N/A | Synaptic Density and Progression of Huntington's Disease. | January 14, 2020 | October 5, 2022 |
| NCT04630574 | Completed | Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers | February 23, 2021 | February 5, 2024 | |
| NCT03417583 | Completed | N/A | Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients | November 9, 2018 | October 10, 2023 |
| NCT03421327 | Completed | Genetic Risk: Whether, When, and How to Tell Adolescents | September 1, 2017 | December 31, 2018 | |
| NCT04201834 | Completed | Phase 2 | Risperidone for the Treatment of Huntington's Disease Involuntary Movements | August 13, 2020 | December 30, 2023 |
| NCT04515550 | Completed | Mitochondrial Biomarkers in Huntington's Disease | April 4, 2019 | February 28, 2022 | |
| NCT03709173 | Completed | FuRST 2.0 Cognitive Pre-testing - Round 2 | August 2, 2019 | October 25, 2019 | |
| NCT04514367 | Completed | Phase 2 | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | August 17, 2020 | January 28, 2022 |
| NCT04421339 | Completed | N/A | Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study | January 22, 2021 | September 16, 2022 |
| NCT03787758 | Completed | Phase 1 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | February 28, 2019 | October 7, 2019 |
| NCT03842969 | Completed | Phase 3 | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies | April 23, 2019 | March 30, 2022 |
| NCT03854019 | Completed | Phase 3 | Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | August 5, 2019 | November 11, 2022 |
| NCT03515213 | Completed | Phase 2 | Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease | April 27, 2017 | August 31, 2021 |
| NCT00075140 | Completed | Family Health After Predictive Huntington Disease (HD) Testing | September 2001 | October 2008 | |
| NCT00146211 | Completed | Phase 3 | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease | September 2005 | July 2007 |
| NCT00190450 | Completed | Phase 2 | MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease | January 2002 | December 2013 |
| NCT00271596 | Completed | Phase 2 | Citalopram to Enhance Cognition in HD | November 2005 | November 2011 |
| NCT00277355 | Completed | Phase 2/Phase 3 | Pilot Study of Minocycline in Huntington's Disease | April 2006 | November 2008 |
| NCT00277602 | Completed | Phase 3 | Riluzole in Huntington's Disease | November 1999 | July 2004 |
| NCT00368849 | Completed | Phase 2 | Atomoxetine and Huntington's Disease | November 2005 | February 2008 |
| NCT00465790 | Completed | Research of Biomarkers in Parkinson Disease | October 2007 | June 2012 | |
| NCT00539747 | Completed | Making Sense of a Positive Genetic Test Result for Huntington Disease | October 1, 2007 | August 5, 2008 | |
| NCT05668520 | Enrolling by invitation | A Pilot Study of Nutritional Status in Patients With Huntington's Disease | October 1, 2022 | October 2023 | |
| NCT05913154 | Enrolling by invitation | Impact of Apathy on Caregiving in HD. Version 1 | April 26, 2023 | December 2023 | |
| NCT06448546 | Not yet recruiting | Gut Microbiomes in HD | June 2024 | June 2029 | |
| NCT05360082 | Not yet recruiting | Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD. | September 2024 | December 2025 | |
| NCT05509153 | Not yet recruiting | Phase 2 | A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers | November 1, 2022 | May 1, 2027 |
| NCT06097780 | Not yet recruiting | Phase 3 | Efficacy and Safety of NestaCell® in Huntington's Disease | June 8, 2024 | February 9, 2026 |
| NCT06147414 | Not yet recruiting | Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders | April 2024 | December 2026 | |
| NCT06194006 | Not yet recruiting | N/A | Long Term Follow-up Grafted Huntington's Disease Patients | January 1, 2024 | January 1, 2034 |
| NCT06444217 | Not yet recruiting | N/A | Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD | July 1, 2024 | July 1, 2028 |
| NCT05828992 | Recruiting | Benchmarking Integrated Care for People Living With Huntington's Disease in England | February 28, 2023 | February 29, 2024 | |
| NCT04394767 | Recruiting | Couple and Spouse Caregiver in Huntington's Disease | January 13, 2020 | February 2025 | |
| NCT04478734 | Recruiting | Phase 2 | Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease | April 12, 2023 | December 30, 2025 |
| NCT03434548 | Recruiting | iMarkHD: In Vivo Longitudinal Imaging of HD Pathology | July 20, 2021 | June 30, 2027 | |
| NCT04713982 | Recruiting | Phase 2/Phase 3 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | November 19, 2021 | April 1, 2025 |
| NCT04818060 | Recruiting | Preparing for Prevention of Huntington's Disease (PREVENT-HD) | September 13, 2021 | February 2026 | |
| NCT04826692 | Recruiting | Phase 3 | TEsting METformin Against Cognitive Decline in HD | December 10, 2021 | August 2024 |
| NCT03233646 | Recruiting | Retinal Imaging in Neurodegenerative Disease | July 20, 2017 | December 31, 2025 | |
| NCT05032196 | Recruiting | Phase 1/Phase 2 | Study of WVE-003 in Patients With Huntington's Disease | September 6, 2021 | December 2024 |
| NCT03034122 | Recruiting | Is Caffeine an Environmental Modifier in Huntington's Disease? | October 11, 2017 | October 2023 | |
| NCT02994719 | Recruiting | Gait Analysis in Neurological Disease | March 1, 2016 | June 20, 2025 | |
| NCT05243017 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | October 7, 2021 | October 7, 2029 |
| NCT05270681 | Recruiting | N/A | Move to Improve: Telehealth Exercise to Music for HD | November 8, 2021 | December 2024 |
| NCT05326451 | Recruiting | N/A | Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | June 21, 2023 | May 1, 2024 |
| NCT05358717 | Recruiting | Phase 2 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | April 25, 2022 | July 31, 2024 |
| NCT06254482 | Recruiting | Phase 2 | An Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | August 25, 2023 | July 20, 2027 |
| NCT06343220 | Recruiting | Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research | April 10, 2024 | September 2024 | |
| NCT05534139 | Recruiting | Clinicopathological MRI and CSF Correlates in Huntington's Disease. | August 11, 2021 | August 31, 2024 | |
| NCT05655520 | Recruiting | Phase 3 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | December 14, 2022 | December 2025 |
| NCT05686551 | Recruiting | Phase 2 | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease. | February 3, 2023 | April 1, 2027 |
| NCT05773196 | Recruiting | Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study | March 14, 2023 | February 28, 2025 | |
| NCT05808153 | Recruiting | N/A | Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression | March 21, 2024 | February 2, 2027 |
| NCT05822908 | Recruiting | Phase 1/Phase 2 | A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD | February 14, 2023 | September 15, 2025 |
| NCT05943054 | Recruiting | N/A | Striatum and Hippocampus on Different Time Scales | January 6, 2023 | March 30, 2026 |
| NCT06024265 | Recruiting | Early Phase 1 | The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease | April 4, 2023 | December 31, 2024 |
| NCT06082713 | Recruiting | Extracellular Vesicles for HD | October 25, 2023 | November 2031 | |
| NCT06414967 | Recruiting | N/A | Study to Evaluate Music Therapy on Irritability and Impulsivity in Patients With Huntington's Disease (MUSIC-HD) | May 15, 2024 | May 20, 2026 |
| NCT06203106 | Recruiting | NYSCF Scientific Discovery Biobank | November 10, 2022 | November 10, 2045 | |
| NCT06216054 | Recruiting | Phase 1 | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects | December 23, 2023 | August 14, 2024 |
| NCT04071639 | Recruiting | Phase 1 | Symptomatic Therapy for Patients With Huntington's Disease | March 12, 2020 | December 31, 2024 |
| NCT04012411 | Recruiting | N/A | Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease | March 3, 2020 | February 2026 |
| NCT04231487 | Recruiting | Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders | June 27, 2019 | December 31, 2022 | |
| NCT04244513 | Recruiting | N/A | Deep Brain Stimulation Treatment for Chorea in Huntington's Disease | February 1, 2020 | December 30, 2023 |
| NCT03810898 | Terminated | Early Phase 1 | iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 | February 9, 2021 | February 15, 2023 |
| NCT02907294 | Terminated | Phase 1 | Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers | March 2016 | May 2016 |
| NCT04617847 | Terminated | Phase 1/Phase 2 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | April 13, 2020 | May 3, 2021 |
| NCT04617860 | Terminated | Phase 1/Phase 2 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | September 24, 2019 | April 29, 2021 |
| NCT03052712 | Terminated | N/A | Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies | September 9, 2016 | September 8, 2019 |
| NCT03886753 | Terminated | Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products | May 15, 2019 | June 30, 2020 | |
| NCT02218567 | Terminated | N/A | Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience | June 2014 | December 2015 |
| NCT03980938 | Terminated | Phase 2 | Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease | July 8, 2019 | October 15, 2020 |
| NCT01085266 | Terminated | Phase 3 | An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease | February 2010 | |
| NCT03344601 | Unknown status | N/A | PHysical Activity and Exercise Outcomes in Huntington's Disease | February 16, 2018 | August 31, 2020 |
| NCT04698551 | Unknown status | NIPD on cffDNA for Triplet Repeat Diseases | September 1, 2020 | December 1, 2023 | |
| NCT03296176 | Unknown status | N/A | Metabolomic Study in Huntington's Disease (METABO-HD) | October 9, 2017 | September 2019 |
| NCT04301726 | Unknown status | Phase 1 | Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD | September 1, 2020 | December 31, 2022 |
| NCT00675077 | Unknown status | Phase 1 | Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD) | May 2008 | June 2010 |
| NCT01834053 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. | September 2014 | June 2016 |
| NCT00052143 | Unknown status | Prospective Huntington At Risk Observational Study | July 1999 | July 2010 | |
| NCT03119246 | Unknown status | N/A | Beta Testing of a New Assessment in Huntington's Disease (HD) | June 2016 | March 2018 |
| NCT01554033 | Unknown status | Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN) | May 2009 | May 2015 | |
| NCT05225051 | Unknown status | N/A | N- Homocysteinylated Huntingtin in Huntington's Disease | April 1, 2022 | May 1, 2023 |
| NCT01412125 | Unknown status | Study of Biomarkers That Predict the Evolution of Huntington's Disease | September 2003 | January 2021 | |
| NCT04257513 | Unknown status | Clinical Study to Monitor Plasma Levels of 24OHC in Subject With HD | October 1, 2019 | September 2022 | |
| NCT04370470 | Unknown status | Development of Assessments for Later Stage HD | September 2020 | March 2022 | |
| NCT00514774 | Unknown status | Phase 1 | Ursodiol in Huntington's Disease | August 2007 | June 2009 |
| NCT03764215 | Unknown status | Phase 1 | Nilotinib in Huntington's Disease | November 15, 2018 | November 30, 2020 |
| NCT04429230 | Unknown status | N/A | Non-invasive Brain Stimulation in Huntington's Disease | September 7, 2021 | December 31, 2022 |
| NCT00313495 | Unknown status | Cooperative Huntington's Observational Research Trial | February 2006 | December 2020 | |
| NCT03713892 | Unknown status | Phase 1 | CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects | May 23, 2018 | December 2020 |
| NCT03599076 | Unknown status | Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease | September 25, 2018 | December 2019 | |
| NCT04589182 | Unknown status | N/A | Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease | October 20, 2020 | October 31, 2022 |
| NCT02563418 | Unknown status | N/A | Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study | May 2014 | |
| NCT04885114 | Withdrawn | Phase 1 | Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease | July 30, 2021 | December 30, 2024 |
| NCT03142217 | Withdrawn | N/A | Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria | March 26, 2015 | March 1, 2017 |
- OrphaNumber from OrphaNet (Orphanet)
- 399
- ICD10 preferred id (Insert disease from ICD10)
- D0005261
- ICD10 class code (Insert disease from ICD10)
- G10
- MeSH unique ID (MeSH (Medical Subject Headings))
- D006816